Ischemia Reperfusion Injury Therapeutics Market to Reach US$ 2,290.1 Million at a CAGR of 5.42% by 2028 | Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited

Ischemia-Reperfusion injury is a complication of severe hypoxia and is caused by a lack of oxygen in the tissues. Lack of oxygen leads to an increase in metabolic intermediates and oxygen radicals. As these molecules increase in numbers, they overwhelm the normal defenses of the cells. The resulting oxidative damage results in damage to vital cell components, leading to death. It is important to treat Ischemia-Reperfusion injury as quickly as possible.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4105

During the first stage of acute MI, myocardial cells are damaged. Without adequate collateral circulation, they die. In fact, the heart can temporarily stop pumping blood to the affected area due to a thrombus. The subsequent reperfusion resupplies the ischemic tissue, but it paradoxically causes further tissue damage. There are a few different ways to treat Ischemia Reperfusion Injury.

Increasing number of partnership and agreements for among key players to For instance, in May 2019, Abiomed received an FDA approval for its STEM DTU trial of delayed ischemic reperfusion injury. This clinical trial will test the hypothesis that unloading the left ventricle for 30 minutes before ischemia and reperfusion injury (IRI) to reduce myocardial damage from a heart attack and decrease in the heart failure-related events in future.

In January 2020, a cannabis life sciences company, Revive Therapeutics Ltd., provided an update regarding its clinical development plan on liver diseases. The company’s aim is to expand its product pipeline by leveraging its U.S. Food and Drug Administration orphan drug designation for Cannabidiol for the prevention of ischemia and reperfusion injury from organ transplantation.

The emergence of drugs for treatment of complications related to ischemia reperfusion and rising number of research & development activities are some of the factors driving growth of the global ischemia reperfusion injury therapeutics. For instance, Faraday Pharmaceuticals in November 2019, announced phase II clinical trials’ positive top-line results of FDY-5301, for ischemia and reperfusion injury treatment.

Key Takeaways of the Global Ischemia Reperfusion Injury Therapeutics Market:

• The global ischemia reperfusion injury therapeutics market is expected to exhibit a CAGR of 4% during the forecast period (2020-2027) owing to increasing research & development of novel therapies and treatments for ischemia and reperfusion injury.
• Among distribution channel, the hospital pharmacy segment is expected to hold the largest revenue share in the market in 2027 due to the growing number of tissue damage cases and ischemia and reperfusion injury. This is mainly because ischemia reperfusion injury is the tissue damage that arises when blood supply returns to the tissue (reperfusion) due to lack of oxygen (ischemia).
• Major players operating in the global ischemia reperfusion injury therapeutics market are Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.

Click Here to Get a Sample Copy (Exclusive Offer: UPTO 30% Discount for A Limited Time) @ https://www.coherentmarketinsights.com/insight/request-sample/4105

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Ischemia Reperfusion Injury Therapeutics Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Ischemia Reperfusion Injury Therapeutics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Ischemia Reperfusion Injury Therapeutics Industry Impact

Chapter 2 Global Ischemia Reperfusion Injury Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Ischemia Reperfusion Injury Therapeutics (Volume and Value) by Type
2.3 Global Ischemia Reperfusion Injury Therapeutics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Ischemia Reperfusion Injury Therapeutics Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 6 East Asia Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 7 Europe Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 8 South Asia Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 9 Southeast Asia Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 10 Middle East Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 11 Africa Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 12 Oceania Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 13 South America Ischemia Reperfusion Injury Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Ischemia Reperfusion Injury Therapeutics Business
Chapter 15 Global Ischemia Reperfusion Injury Therapeutics Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology